Eli Lilly reported a strong second quarter with revenue of $22.97 billion, surpassing expectations, and earnings per share (EPS) of $8.38, beating consensus by over 27%. The growth was driven by a 91% increase in sales of its obesity drug Mounjaro, boosted by international expansion including China. Management raised its full-year revenue guidance to $85-$87 billion and increased its performance margin forecast. The company’s stock rose nearly 10% last week, with a bullish outlook supported by upcoming drug launches like retatrutide and Foundayo. Risks include pricing pressures and reliance on key drugs, but overall momentum and pipeline prospects remain strong.
Vanguard's VTSAX mutual fund, though low-cost on paper, can incur significant hidden expenses like capital gains taxes, a $3,000 minimum investment, and transaction fees outside Vanguard platforms. Its ETF counterpart, VTI, offers the same broad US m...
Wave Life Sciences shares are down significantly this year, trading near their 52-week low with a market cap around $1 billion. The company, focused on RNA-based medicines, holds substantial cash but is currently unprofitable. Its key assets include ...
Novo Nordisk CEO Mike Doustdar defended the company's lawsuit against Eli Lilly, accusing Lilly of misleading advertising about their weight-loss drug efficacy. Novo argues that Lilly's ads compare Lilly's Zepbound to an older, lower-dose version of ...
Eli Lilly reported strong sales growth for its drugs Mounjaro, Jaypirca, and Omvoh, with Jaypirca sales up 56.4% year-on-year to $192 million in Q2 despite competition. The company’s Retatrutide showed promising results in obesity trials, potentially...
Novo Nordisk CEO Mike Doustdar highlighted the early stage of GLP-1 drug adoption for obesity treatment, noting that over 100 million Americans suffer from obesity but only about 10-15% have used these medications. He emphasized the potential for the...
